197 related articles for article (PubMed ID: 15932789)
1. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages.
Suzuki E; Sugiyama C; Umezawa K
Biomed Pharmacother; 2009 Jun; 63(5):351-8. PubMed ID: 18635336
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E; Umezawa K
Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
[TBL] [Abstract][Full Text] [Related]
4. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
5. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
6. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
Suzuki E; Ninomiya Y; Umezawa K
Biochem Biophys Res Commun; 2009 Feb; 379(2):379-83. PubMed ID: 19103154
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
9. Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Shinoda K; Nakagawa K; Kosaka T; Tanaka N; Maeda T; Kono H; Mizuno R; Kikuchi E; Miyajima A; Umezawa K; Oya M
Hum Immunol; 2010 Aug; 71(8):763-70. PubMed ID: 20573582
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
12. 5-Chloroacetyl-2-amino-1,3-selenazoles attenuate microglial inflammatory responses through NF-kappaB inhibition.
Nam KN; Koketsu M; Lee EH
Eur J Pharmacol; 2008 Jul; 589(1-3):53-7. PubMed ID: 18538761
[TBL] [Abstract][Full Text] [Related]
13. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, prevents inflammatory injury induced by interferon-gamma and histamine in NCTC 2544 keratinocytes.
Cardile V; Libra M; Caggia S; Frasca G; Umezawa K; Stivala F; Mazzarino MC; Bevelacqua Y; Coco M; Malaponte G
Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):679-83. PubMed ID: 20337659
[TBL] [Abstract][Full Text] [Related]
14. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
[TBL] [Abstract][Full Text] [Related]
15. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
[TBL] [Abstract][Full Text] [Related]
16. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
Horiguchi Y; Kuroda K; Nakashima J; Murai M; Umezawa K
Expert Rev Anticancer Ther; 2003 Dec; 3(6):793-8. PubMed ID: 14686701
[TBL] [Abstract][Full Text] [Related]
18. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
19. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
Funakoshi T; Yamashita K; Ichikawa N; Fukai M; Suzuki T; Goto R; Oura T; Kobayashi N; Katsurada T; Ichihara S; Ozaki M; Umezawa K; Todo S
J Crohns Colitis; 2012 Mar; 6(2):215-25. PubMed ID: 22325176
[TBL] [Abstract][Full Text] [Related]
20. Bee venom and melittin reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia.
Moon DO; Park SY; Lee KJ; Heo MS; Kim KC; Kim MO; Lee JD; Choi YH; Kim GY
Int Immunopharmacol; 2007 Aug; 7(8):1092-101. PubMed ID: 17570326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
